Source comparison
Ipamorelin Before and After: Growth Hormone Secretagogue Comparison
Ipamorelin Selective ghrelin receptor agonist (GHS-R1a only) 200–300mcg 2–3x daily 2–3 hours Minimal. No cortisol or prolactin elevation Best option for lean recomposition without unwanted hormone disruption. Clean GH pulse with no downstream metabolic interfe
This comparison does not assign a generated winner or score.
- Ipamorelin
- Selective ghrelin receptor agonist (GHS-R1a only)
- 200–300mcg 2–3x daily
- 2–3 hours
- Minimal. No cortisol or prolactin elevation
- Best option for lean recomposition without unwanted hormone disruption. Clean GH pulse with no downstream metabolic interference
- GHRP-6
- Non-selective ghrelin receptor agonist
- 100–200mcg 2–3x daily
- Increased appetite, mild water retention, cortisol elevation
- Effective but less refined. Hunger stimulation makes adherence difficult during caloric deficit phases
- CJC-1295 (with DAC)
- Growth hormone releasing hormone (GHRH) analog
- 2mg every 7 days
- Sustained elevation for 5–7 days
- Potential pituitary desensitization with chronic use
- Pairs well with ipamorelin for synergistic effect but requires cycling to prevent receptor downregulation
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 10–25mg once daily
- 24-hour sustained elevation
- Increased appetite, insulin resistance risk, water retention
- Convenient oral administration but broader metabolic effects. Not ideal for users prioritizing body composition over convenience
- The comparison makes clear why ipamorelin dominates research protocols focused on body recomposition: it produces targeted GH elevation without appetite stimulation, cortisol spikes, or insulin sensitivity impairment. Real ipamorelin before and after results reflect pure anabolic signaling, not the metabolic noise created by non-selective secretagogues.